W
WAVEMAN · COMPANY
LENZ · Lenz Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

LENZ

LENZ Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001815776
CLUSTER · 3 INSIDERSC-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$365.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
85
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-430.3%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$365.6K over 180 days
more than 82% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
85 funds added or opened last quarter
more than 59% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
-430.3% net margin
below 81% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
36.0% of shares outstanding short · 11.8 days to cover · settled 2026-07-31
the highest in Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders independently bought a net $365.6K while the stock fell 49% over six months — no planned sales are queued against it.
85 funds added or opened positions in the latest 13F quarter, of 146 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -84.8%
-84.8%12M
-88%-51%-13%+25%2025-092025-102025-122026-032026-052026-072026-09 2025-09-30 · Versant Vantage II GP-GP, LLC sold $3.9M2025-09-30 · Versant Vantage II GP-GP, LLC sold $2.7M2025-09-30 · Versant Vantage II GP-GP, LLC sold $2.3M2025-09-18 · Versant Venture Capital VI, L.P. sold $2.1M2025-09-18 · Versant Venture Capital VI, L.P. sold $1.8M2025-09-30 · Versant Vantage II GP-GP, LLC sold $1.6M2025-09-18 · Versant Venture Capital VI, L.P. sold $1.0M2025-09-18 · Versant Venture Capital VI, L.P. sold $866.4K2026-03-27 · Schimmelpennink Evert B. bought $251.4K2025-11-07 · MCCOLLUM JAMES W bought $239.3K2025-11-17 · Olsson Shawn sold $152.6K2025-11-17 · Olsson Shawn sold $108.4K2026-03-27 · Chevallard Daniel R. bought $64.3K2026-03-27 · George Jeffrey P. bought $49.9K2025-11-07 · Chevallard Daniel R. bought $49.6K2025-09-18 · Versant Venture Capital VI, L.P. sold $11.6K2025-09-30 · Versant Vantage II GP-GP, LLC sold $8.3K2025-09-30 · Versant Vantage II GP-GP, LLC sold $5.8K2025-09-18 · Versant Venture Capital VI, L.P. sold $5.7K2025-11-07 · Chevallard Daniel R. bought $454
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $365.6K bought by insiders over 180 days, 85 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, LENZ Therapeutics, Inc. insiders bought a net $365.6K of stock across 46 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
George Jeffrey P.
Director
BUY
2026-03-27
5,592.0
$49.9K
Schimmelpennink Evert B.
President, CEO and Secretary
BUY
2026-03-27
28,089.0
$251.4K
Chevallard Daniel R.
Chief Financial Officer
BUY
2026-03-27
7,500.0
$64.3K
Olsson Shawn
Chief Commercial Officer
SELL
2025-11-17
4,212.0
$108.4K
Olsson Shawn
Chief Commercial Officer
SELL
2025-11-17
5,788.0
$152.6K
46 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 41 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
4,178,823.0 sh
$23.7M
Alpha Wave Global, LP
3,612,211.0 sh
$20.5M
FMR LLC
3,558,905.0 sh
$20.2M
Versant Venture Management, LLC
2,656,888.0 sh
$15.1M
BlackRock, Inc.
2,292,121.0 sh
$13.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Etf
$468.5K POSITION · AS OF 2026-04-30
0.8%
Franklin Biotechnology Discovery Fund
$1.7M POSITION · AS OF 2026-04-30
0.2%
Harbor Human Capital Factor US Small Cap ETF
$125.7K POSITION · AS OF 2026-04-30
0.1%
Franklin Small Cap Growth Fund
$1.4M POSITION · AS OF 2026-04-30
0.1%
iShares U.S. Pharmaceuticals ETF
$560.2K POSITION · AS OF 2026-03-31
0.1%
PRIMECAP Odyssey Aggressive Growth Fund
$3.6M POSITION · AS OF 2026-04-30
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$19.1M$0——
OPERATING INCOME$-91.1M$-58.6M$-72.4M$-105.6M
NET INCOME$-82.1M$-49.8M$-70.0M$-101.1M
EPS (DILUTED)-2.85-2.34-35.71-1.84
OPERATING CASH FLOW$-69.2M$-59.4M$-60.4M$-88.0M
CASH$25.2M$20.2M$35.1M$47.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →